NCT04801160 is a NA clinical trial of REMS+TAI in Unresectable Hilar Cholangiocarcinoma, sponsored by Zhongda Hospital.

Who is sponsoring NCT04801160?

NCT04801160 is sponsored by Zhongda Hospital.

What drugs are being tested in NCT04801160?

Interventions in NCT04801160: REMS+TAI, SEMS+TAI.

What condition does NCT04801160 study?

NCT04801160 studies Unresectable Hilar Cholangiocarcinoma.

Is NCT04801160 still recruiting?

NCT04801160 is currently completed. Last updated 18 December 2023.

Last reviewed 2023-12-18 · How we verify

NCT04801160

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

REMS Combined With TAI for Unresectable HC

Completed NA Last updated 18 December 2023

What this trial tests

NA trial testing REMS+TAI in Unresectable Hilar Cholangiocarcinoma in 126 participants. Completed in 15 July 2023.

Timeline

1 March 2021

Primary endpoint
15 July 2023

15 July 2023

Quick facts

Lead sponsor	Zhongda Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	126
Start date	1 March 2021
Primary completion	15 July 2023
Estimated completion	15 July 2023
Sites	1 location across China

Drugs / interventions tested

REMS+TAI
SEMS+TAI

Conditions studied

Unresectable Hilar Cholangiocarcinoma — all drugs for Unresectable Hilar Cholangiocarcinoma →

Sponsor

Zhongda Hospital

Who can join

18 and older, any sex, with Unresectable Hilar Cholangiocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this randomized controlled study is to evaluate the efficacy and safety of the Radiation-Emitting Metallic Stents (REMS) combined with Trans-Arterial Infusion (TAI) for unresectable hilar cholangiocarcinoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Radiation-emitting metallic stent for unresectable Bismuth type III or IV perihilar cholangiocarcinoma: a multicenter randomized trial.
Chen Q, Ge NJ, Li YL, Huang M, et al · · 2025 · cited 3× · PMID 39311927 · DOI 10.1097/js9.0000000000002089

Verify or expand the search:

Other Zhongda Hospital trials

Trials by the same sponsor.

NCT07516704 — Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoa · EARLY_PHASE1 · not yet recruiting
NCT07504731 — Trunk Inclination, Positive End-expiratory Pressure, and Lung Recruitability · recruiting
NCT07351669 — A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepato · recruiting
NCT07311915 — Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in Hi · NA · not yet recruiting
NCT07585877 — Effect of Branched-Chain Amino Acid Supplementation on Myopia Progression · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04801160 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhongda Hospital
Last refreshed: 18 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04801160.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing